Non-clinical toxicology: support for toxicological, genotoxicity, carcinogenicity and reproductive toxicity assessments in the safety of medicines, including in silico modelling to enhance safety evaluations. Biological safety, and sterilisation and decontamination assessment: underpinning both post-market surveillance and clinical investigations for medical devices. Pharmacogenomics for pharmacovigilance: co-ordinate policy on the integration of pharmacogenomics with pharmacovigilance to support personalised medicine, ensuring our approach remains at the forefront of healthcare. Emerging technologies: lead policy on post-market surveillance and risk assessment of diagnostics, as well as emerging and advanced technologies such as nano-enabled medicines and devices, ATMPs (Advanced Therapy Medicinal Products), and synthetic biology products.
Beware of fraud agents! do not pay money to get a job
MNCJobs.co.uk will not be responsible for any payment made to a third-party. All Terms of Use are applicable.